Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Back to Search
Print
Bookmark Trial

NCT01776437

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Covance Clinical Research Unit Inc.
Evansville, Indiana, 47710, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Human Volunteers
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male, between the ages of 18 and 55.

- Non-smoking for at least 1 year before Screening.

- Willing and able to provide informed consent.

- Have a BMI between 18 to 30kg/m2.

- Willing and able to comply all study procedures.

- Have adequate organ function

- Sexually active patients must be willing to use an acceptable method of contraception.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of any illness that might confound the results of the study or pose an
additional risk in administering study medication to the subject.


- Current use of prescription medication or regular treatment with over-the-counter
medications.


- Consumption of herbal medications or dietary supplements.


- Consumption of more that than 3 units of alcoholic beverages per day.


- Consumption of more than five 240-mL servings of coffee or other caffeinated beverage.


- History of alcohol or drug abuse or addiction within 6 months of study entry.


- Participation in a clinical Study involving administration of an investigational drug
within 1 month or 5 half lives (whichever is longer).


- Donation of any blood or having had a significant loss of blood with 56 days.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Human VolunteersA Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects NCT01468714
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Human VolunteersStudy of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers NCT01776437
  1. Evansville, Indiana
Male
18 Years+
years
MULTIPLE SITES
Human VolunteersDrug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics NCT01445860
  1. Singapore,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
Official Title  ICMJE A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers
Brief Summary This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Human Volunteers
Intervention  ICMJE Drug: BMN 673
500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
Study Arms  ICMJE
  • Experimental: Treatment A
    Period 1: fasted control ? Period 2: fed control
    Intervention: Drug: BMN 673
  • Experimental: Treatment B
    Period 1: fed control ? Period 2: fasted control
    Intervention: Drug: BMN 673
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 24, 2013)		18
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2013
Actual Primary Completion Date May 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male, between the ages of 18 and 55.
  • Non-smoking for at least 1 year before Screening.
  • Willing and able to provide informed consent.
  • Have a BMI between 18 to 30kg/m2.
  • Willing and able to comply all study procedures.
  • Have adequate organ function
  • Sexually active patients must be willing to use an acceptable method of contraception.

Exclusion Criteria:

  • History of any illness that might confound the results of the study or pose an additional risk in administering study medication to the subject.
  • Current use of prescription medication or regular treatment with over-the-counter medications.
  • Consumption of herbal medications or dietary supplements.
  • Consumption of more that than 3 units of alcoholic beverages per day.
  • Consumption of more than five 240-mL servings of coffee or other caffeinated beverage.
  • History of alcohol or drug abuse or addiction within 6 months of study entry.
  • Participation in a clinical Study involving administration of an investigational drug within 1 month or 5 half lives (whichever is longer).
  • Donation of any blood or having had a significant loss of blood with 56 days.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01776437
Other Study ID Numbers  ICMJE 673-103
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Pfizer
Verification Date July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP